TrialJournal for immunotherapy of cancer2026

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Vicky Makker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.